A Functional Medicine Perspective on Genetics and Chronic Fatigue Syndrome

Yoon Hang Kim MD

I've been prescribing Low Dose Naltrexone for over two decades now, and one question comes up more than almost any other: "Why did LDN work miracles for my friend but barely touched my symptoms?"

The answer - a partial answer - may lie in your genetics. And today I want to walk you through one gene in particular—OPRM1—that may help explain not just your response to LDN, but how your body processes pain, regulates immunity, and sustains the chronic inflammatory state that characterizes ME/CFS.

First, A Reality Check About Genetic Testing

Before we dive in, I want to be honest with you—the same way I'm honest with my patients. Understanding the link between your genetics and ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) is a bit like looking at a single gear in a very complex machine.

That gear matters. It absolutely matters. But it's not the whole machine.

ME/CFS is what we call polygenic—it's driven by hundreds, maybe thousands, of small genetic variations working in concert with environmental triggers like viral infections, mold exposure, or major life stressors. So when you get your genetic test results back and see a particular variant, resist the urge to think you've found "the answer." What you've found is a clue. A useful one. But still just one piece of a much larger puzzle.

With that framing in mind, let's talk about OPRM1.

What Is OPRM1 and Why Should You Care?

The OPRM1 gene provides instructions for making the mu-opioid receptor. Think of this receptor as a docking station—it's the primary site in your brain and immune system where endorphins (your body's natural "feel-good" chemicals) and opioid medications bind.

When endorphins dock at these receptors, they reduce pain, create feelings of well-being, and modulate immune function. When the receptors don't work optimally—or when you don't have enough endorphins to fill them—problems emerge.

Here's what makes this relevant to ME/CFS: the mu-opioid receptor isn't just about pain. It sits at the intersection of your nervous system and immune system. It influences how your body responds to stress, how it regulates inflammation, and how effectively your natural killer cells function.

In other words, this one receptor touches on nearly every major dysfunction we see in ME/CFS.

Understanding the rs1799971 SNP: The A118G Variation

When we test the OPRM1 gene, we're typically looking at a specific location called rs1799971, often referred to as A118G. At this location, you can have one of three combinations:

AA (Wild Type): This is the most common version globally. You have two copies of the "A" allele. Your mu-opioid receptors generally function at "normal" or high-efficiency levels.

AG (Heterozygous): You have one copy of each allele. Receptor function is somewhat reduced compared to AA.

GG (Homozygous Variant): You have two copies of the "G" allele. People with this genotype typically have fewer mu-opioid receptors or receptors that don't signal as effectively.

Let me walk through what each of these might mean for someone living with ME/CFS.

The AA Genotype: When "Normal" Receptors Meet an Abnormal Illness

If you're AA at rs1799971, your receptors are structurally "normal." In theory, your body is well-equipped to use its own endorphins. This sounds like good news, and in many contexts, it is.

But here's the clinical reality I see in my practice: in ME/CFS, the problem often isn't the receptor itself. It's everything upstream and downstream of that receptor.

Pain Processing in AA Individuals

This is where it gets counterintuitive. You might expect that "normal" receptors would mean less pain sensitivity. But several studies have found that the AA genotype is actually associated with a lower pressure-pain threshold.

What does this mean practically? If you're AA, you may be more sensitive to physical pain, tender points, and pressure compared to someone with the G variant. Your receptors work fine—they're just receiving a lot of painful signals.

In the context of ME/CFS, where central sensitization (an amplified pain response from the nervous system) is common, this can translate to significant suffering even when there's no obvious tissue damage.

Endorphin Efficiency vs. Endorphin Availability

Here's a concept I call "endorphin reserve" that I find useful clinically. Your AA genotype means you have efficient receptors, but efficiency means nothing if the tank is empty.

Many of my ME/CFS patients are profoundly depleted. They've been sick for years. They don't sleep restoratively. Their stress response systems are dysregulated. In this state, even perfect receptors can't compensate for the lack of available neurochemicals.

Think of it like having a beautiful, well-maintained car but no gas in the tank. The engineering is fine. The fuel isn't there.

Immune Function and Natural Killer Cells

One of the most consistent findings in ME/CFS research is reduced Natural Killer (NK) cell cytotoxicity. These immune cells, which are supposed to patrol your body and eliminate infected or abnormal cells, simply don't work as well in ME/CFS patients.

Here's where OPRM1 comes in: mu-opioid receptors aren't just in your brain. They're on your immune cells, including NK cells.

Some research suggests that the AA genotype allows for more "normal" modulation of immune function through the opioid pathway. In a healthy person, this is advantageous. But in the hyper-reactive, chronically inflamed state of ME/CFS, it can play a role in how the body sustains that inflammation or responds to stressors.

It's not that AA causes immune dysfunction—it's that in the context of ME/CFS, even "normal" immune modulation pathways get pulled into the dysfunction.

The G Allele: A Different Set of Trade-Offs

If you carry one or two copies of the G allele (AG or GG), you have a different set of considerations.

Reduced Receptor Expression

The G variant is associated with fewer mu-opioid receptors and reduced receptor signaling efficiency. In pain management contexts, this often means requiring higher doses of opioid medications to achieve the same effect.

Potential Protective Effects

Interestingly, some research suggests the G variant may offer certain protective effects in chronic pain conditions. With fewer receptors firing, there may be less central sensitization over time. This is speculative and not consistent across studies, but it's a hypothesis worth considering.

LDN Response Implications

This is where it gets clinically relevant for my practice. LDN works by briefly blocking mu-opioid receptors to upregulate endorphin production. If you have fewer receptors to begin with (the G variant), the dynamics of this blockade change.

Some G-variant patients need different dosing strategies. Some respond better to ultra-low doses in the microgram range. Others may need the combination protocols I discuss in my LDN Primer—adding ketotifen for mast cell stabilization, or methylene blue for mitochondrial support.

How This Affects Your Response to Low Dose Naltrexone

Let me be direct about what I see clinically, because this is where genetics meets real-world treatment decisions.

If You're AA:

You generally have the receptor architecture that LDN was "designed" to work with. The brief receptor blockade should trigger a compensatory increase in endorphin production, which your efficient receptors can then utilize.

However—and this is important—about one-third of patients don't respond to standard LDN protocols regardless of genotype. If you're AA and not responding, the issue likely isn't your receptors. It's probably:

• Severely depleted endorphin reserves (your body can't make more endorphins even when prompted)
• Overwhelming inflammation that LDN alone can't address
• Co-existing conditions like mold toxicity, MCAS, or chronic infections that need to be addressed first
• Dosing issues (some AA patients actually do better at lower doses)

If You're AG or GG:

Standard dosing may not be optimal for you. Consider:

• Starting lower and titrating more slowly
• Microgram dosing (ultra-low dose naltrexone) as an alternative approach
• Combination protocols that support the pathways LDN targets from multiple angles

I've seen G-variant patients who failed standard LDN dosing go on to have excellent responses when we dropped to 0.5mg or even microgram ranges. The receptor dynamics are different, and the dosing should reflect that.

Beyond OPRM1: The Bigger Genetic Picture

If you're tracking your genetics for treatment purposes—and I encourage this—OPRM1 is just one relevant gene. In ME/CFS, we often look at:

Methylation Genes (MTHFR, COMT, etc.): These affect how you process B vitamins, neurotransmitters, and toxins. Dysfunction here can impair energy production and detoxification.

Mitochondrial Function Genes: ME/CFS is increasingly understood as a disorder of cellular energy production. Genetic variations affecting mitochondrial function can predispose to or perpetuate fatigue.

Inflammatory and Immune Genes: Variations in genes controlling cytokine production, immune cell function, and inflammatory responses all play roles.

Detoxification Genes: How efficiently you clear toxins can influence your susceptibility to environmental triggers.

What To Do With This Information

If you've had genetic testing done and you're looking at your OPRM1 results, here's my practical advice:

1. Share This Data With Your Clinician

This isn't information to act on alone. A clinician experienced with both ME/CFS and LDN therapy can integrate your genetic data with your clinical picture to optimize treatment.

2. Don't Use Genetics as a Reason Not to Try LDN

I've seen patients with "unfavorable" genetics respond beautifully to LDN, and patients with "favorable" genetics not respond at all. Genetics loads the gun; environment and treatment pull the trigger. Your genotype influences probability, not destiny.

3. Consider Your "Endorphin Reserve"

Regardless of your OPRM1 status, ask yourself: How depleted am I? How long have I been sick? Do I sleep restoratively? What's my functional capacity?

If you're severely depleted, you may need to support your system more broadly before expecting LDN to work optimally. This might mean addressing sleep, reducing inflammatory triggers, supporting adrenal function, or treating underlying infections.

4. Be Patient With Dosing

If you're not responding to standard doses, don't give up. The dose-response curve with LDN is not linear. Some patients need higher doses (up to 6mg or beyond for certain conditions). Others need microgram doses. Finding your optimal dose takes time and careful observation.

5. Look at the Whole Machine

Remember that single gear analogy? Your OPRM1 status is one gear. The machine includes your methylation capacity, your mitochondrial function, your mast cell stability, your toxic burden, your sleep quality, your stress response, and dozens of other factors.

Effective treatment addresses the whole system, not just one gene.

The Bottom Line

Your OPRM1 genotype isn't a cause of ME/CFS. It's a modulator. It influences the volume of your pain signaling, how your immune system communicates with your nervous system, and potentially how you respond to treatments like LDN.

If you're AA, you have "standard" receptor function—but that doesn't guarantee an easy course or automatic treatment success. If you carry the G variant, you have different receptor dynamics that may require adjusted treatment approaches.

Either way, the path forward involves understanding your unique biology, working with experienced clinicians, and approaching treatment with both optimism and realistic expectations.

ME/CFS is complex. Your genetics are part of that complexity. Understanding them—without obsessing over them—can help guide better treatment decisions.

___

Dr. Yoon Hang Kim is a board-certified preventive medicine physician specializing in integrative and functional medicine. He has been prescribing LDN for over two decades and has presented at multiple LDN Research Trust conferences. He practices telemedicine through Direct Integrative Care, serving patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas.

For more information about LDN therapy, visit directintegrativecare.com or download the free LDN Primer.

Keywords: functional medicine, genetics, LDN, low dose naltrexone, ME/CFS, chronic fatigue syndrome, OPRM1, mu-opioid receptor, integrative medicine, personalized medicine